cyrilzakka/clinical-trials huggingface dataset:
Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial

Addition of clonidine to an epidural mixture of local anaesthetic and morphine improves analgesia and reduces the frequency of motor blockade during epidural analgesia. several side effects are possible mostly somnolence and hypotension. Association of continuous clonidine infusion with low concentrations of levobupivacaïne and sufentanil was not studied during labour. The objective of this study is to compare the effectiveness and the side effects of a PCEA with levobupivacaïne 0,0625 % and sufentanil 0.25 microg.ml-1, without addition of clonidine, and with addition of clonidine at a concentrations of 2 microg.ml-1.


Eligibility Criteria:
Inclusion Criteria:

* Patients of ASA class I or II
* Variable parity
* Aged of 18 years or more
* With a normal pregnancy
* Cervical dilation between 3 and 8 cm)
* Wishing an epidural analgesia
* Normal childbirth
* Giving their written assent
* Affiliated with a social security system
* Must have had an anaesthesia consultation more than 48 hours before inclusion.

Exclusion Criteria:

* Request of the patient
* Failure of epidural analgesia
* Childbirth in the 90 minutes following the induction of analgesia
* Realization of a Caesarean section
Effects of tDCS in M1 and DLPFC on Pain Processing in Healthy Volunteers

The purpose of this study is to evaluate the effects of a direct current applied transcranial over two cortical areas on healthy volunteers' pain processing.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 40 years
* Comprehension of the study tasks

Exclusion Criteria:

* Presence of pain in the previous 6 months
* Altered sensitivity in the tested regions
* Intolerance to electrotherapy
* Presence of pacemakers or any other implanted device
* Ulcers or scars in the skin at the location of the electrodes
* Treatment with direct current stimulation within one week
* Pregnancy
* Frequent headaches
* Epilepsy
* History of neuromuscular disease
* Previous clinical history of cervical surgery
* Injuries or surgery affecting the upper limb
* diabetes mellitus
* Cardiovascular diseases
* Oncological diseases
* Consumption of analgesic drugs 7 days before the study
Helping Youth Smokers Stop Smoking Through the Youth Quitline Programme

The aims of the present study are:

1. To raise the awareness of smoking cessation service among youth smokers in Hong Kong;
2. To provide smoking cessation quitline service to youth smokers; and
3. To provide training to teenagers as peer smoking cessation counsellors.
4. To examine the effectiveness of adventure-based training and WhatsApp messages in helping youth smokers to quit

In Hong Kong, the demand of smoking cessation service of Youth was increasing in the past 10 years, the first youth-oriented smoking cessation hotline "Youth Quitline" was established in 2005. From August 2005 to July 2016, "Youth Quitline" has received over 9,267 telephone inquiries and provided telephone smoking cessation counselling for 1,952 youth smokers.

Youth smokers are recruited using the reactive and proactive strategies. The operation hours of Quitline service are weekdays from 17:00 to 21:00 and on weekends from 14:00 to 20:00. A questionnaire asking the smoking status, reason of smoking, dependency level, knowledge, attitude and practice of smoking or quitting at baseline, the perceived barriers of the smokers and the use of other tobacco products were designed to assess the status of participants, brief counselling with the use of motivational intervention approach is delivered during the phone call.

Telephone counseling at 1-week, 1-month, 3-month, 6-month, 9-month, 12-month and follow-up at 24-month are conducted with the participants to assess their smoking status (by questionnaire) and reinforce intervention (encourage quitting and providing quitting tips). Self-reported quitters who have quitted smoking for at least 7 days at 6-month are invited to perform saliva cotinine test (using NicAlert strip) plus exhaled carbon monoxide text to validate the smoking status.

A qualitative interview will be conducted to investigate the use of other tobacco products of the Youth Quitline participants, and aimed to find out their smoking patterns and feelings of using these products, and how these products might affect quitting or smoking, and how the protest activates influence the smoking behaviors among the youth smokers.

Eligibility Criteria:
Inclusion Criteria:

* Hong Kong resident aged 25 or below
* Able to communicate in Chinese (Cantonese)
* Smoked in the past 30 days

Exclusion Criteria:

* Have difficulty to communicate via telephone
* Having queries irrelevant to tobacco control
Effects of Birth Weight on Anterior Eye Segment Measurements in Full-Term Children by Galilei Dual-Scheimpflug Analyzer

This study evaluates the effects of birth weight (BW) on ocular anterior segment parameters in preschool children using the Galilei Dual-Sheimpflug Analyzer (GD-SA). Children were measured by GD-SA and relationships between all anterior segment parameters obtained by this device and birth weight were analyzed.

Preschoolers, who were born heavier, had thicker cornea and lens, longer axial length, and flatter corneal curve. The thicknesses and axial curves of central cornea within 7mm may be particularly associated with BW.

Eligibility Criteria:
Inclusion Criteria:

* ages 3- 6 years;
* birth weight \>2,500 g;
* gestational age (i.e., the period of time between the first day of the mother's last menstrual period and birth) \>37 weeks;
* visual acuity \>0.8 (in decimals);
* no history of any systemic or ocular diseases;
* no history of previous ocular surgeries;
* no retinopathy of prematurity;
* no current medications; and
* no retinal or optic disc abnormalities on fundoscopy.

Exclusion Criteria:

* ages \<3 \>6 years;
* birth weight \<2,500 g;
* gestational age (i.e., the period of time between the first day of the mother's last menstrual period and birth) \<37 weeks;
* visual acuity \<0.8 (in decimals);
* history of any systemic or ocular diseases;
* history of previous ocular surgeries;
* retinopathy of prematurity;
* current medications; and
* retinal or optic disc abnormalities on fundoscopy.
Photobiomodulation for Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer

Double-blind Superiority Randomized Controlled Clinical Trial. Objective of the study: To evaluate the effectiveness of photobiomodulation using the LED board in the prevention of peripheral neuropathy in the lower limbs in women with breast cancer undergoing chemotherapy at the Cancer Hospital III of the National Cancer Institute (HCIII/INCA).

Materials and methods: This is a single-blind superiority randomized controlled clinical trial. Women aged over 18 years, with breast cancer in stages I to IIIC and who have an indication for curative treatment with neoadjuvant or adjuvant chemotherapy at HCIII/INCA will be eligible. Patients with a previous diagnosis of another primary cancer will be excluded; patients undergoing surgery and/or chemotherapy at another institution; patients who previously had altered sensitivity in the feet; patients who are unable to answer the questionnaires and patients unable to receive photobiomodulation due to acute infections in the lower limbs. After recruitment, the women will be allocated into three groups: two Intervention groups (use of the IV and V LED board; and IV, V and Violet) and a Control group (use of the LED board without light emission). Peripheral neuropathy, pain, global muscle strength, body balance, sensitivity, health-related quality of life and related independent variables will be evaluated, such as the characteristics of the patient, the tumor and the oncological treatment performed. Data analysis: Statistical analysis will be conducted following intention-to-treat principles. Data normality will be tested using the Kolmogorov Smirnov test, considering as normal distribution those with p \> 0.05.

Eligibility Criteria:
Inclusion Criteria:

* Women aged over 18 years, with breast cancer in stages I to IIIC and who have an indication for curative treatment with neoadjuvant or adjuvant chemotherapy in HCIII/INCA.

Exclusion Criteria:

* Patients with a previous diagnosis of another primary cancer
* Patients undergoing surgery and/or chemotherapy at another Institution
* Patients who previously had altered sensitivity in the feet
* Patients who are unable to respond to questionnaires
* Patients unable to receive photobiomodulation due to acute lower limb infections
Predictive Model for Prognosis of Chronic HBV Infection Mothers

Pregnancy is a complex and coordinated physiological process. Pregnancy and the postpartum period are associated with unique changes in the immune system that may impact the natural history of autoimmune diseases and immune-mediated infections. In the postpartum period. ALT ﬂares have been reported in 20%-60% of untreated women and were more likely to occur in hepatitis B e antigen (HBeAg)-positive patients. It has been postulated that postpartum ALT ﬂares may arise to rapid immune restitution against hepatitis B virus (HBV) antigens in the liver, when may be a timing of antiviral treatment. A large number of previous studies have focused on studies on the interruption of mother-to-child transmission in women with chronic hepatitis B(CHB), but studies on the prognosis of mothers undergoing pregnancy and delivery are very limited. What are the factors that affect the clearance of HBeAg or HBsAg? What kind of antiviral treatment protocol should be adopted for mothers with CHB? It is not only a problem that needs to be solved urgently in clinical practice, but also can provide some clues for understanding the occurrence and development of HBV infection in women of childbearing age.

Overall, this study intends to carry out a multi-center two-way cohort study on E antigen-positive CHB women in 9 hospitals in Shaanxi Province. To observe the dynamic changes of virological parameters in these patients, figure out the factors of the serum HBsAg loss and HBeAg seroconversion, and establish relevant predictive models.


Eligibility Criteria:
Inclusion Criteria:

* Age 20-45 years old
* Serum HBsAg positive\> 6 months
* HBeAg positive at delivery
* Good compliance

Exclusion Criteria:

* Women who give birth to stillbirth due to various reasons
* Coinfection with HIV,HCV, syphilis or other sexually transmitted diseases
* Severe kidney, cardiovascular, lung, nervous system or immune system diseases
* Who are taking immunotherapy drugs or anti-tumor drugs
Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones

The present study is a non-interventional retrospective chart review study assessing the prevalence of PNH-clones in patients with PNH risk-factors aged ≥14 years and treated at our hospital. The objective of this study is to develop a PNH screening tool on the hospital Electronic Health Record (EHR) system. An algorithm defining PNH risk groups is developed.

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a life-threatening hematological disorder, but with an effective therapy. Prevalence is estimated between 1-5 per million people, often manifested by cardiovascular, gastrointestinal, neurological or haematological symptoms. Referral is therefore typically to several specialists, resulting in PNH underdiagnosis.

This chart review study consists primarily of developing an algorithm to identify a high-risk cohort of potential PNH patients who need treatment from all registered patients, with maximum ability to find relevant cases. Secondly, this cohort will be manually reviewed by clinicians for final screening. The challenge hence is maximizing the ability to find all relevant PNH patients yet limiting the number to ensure manual review is possible.

Eligibility Criteria:
Inclusion Criteria:

* Patient ≥14 years of age
* At least 1 record encoded in the General Hospital Delta (AZ Delta) patient database (HiX) between 20 April 2018 and 1 March 2022
* A history or presence of at least one PNH risk factors identified following retrospective screening of electronic patient records

Exclusion Criteria:

* None
HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer

Human papillomavirus infections 16 (HPV16) is known to be a high-risk factor to induce cervical cancers. To date, HPV16-related cervical cancer is still a major concern in developing countries where vaccination is not prevalent. Concurrent therapies for cervical cancers have limited response rate and high chance of relapse. However, HPV16-induced cancers provided an ideal target for T cell-based immunotherapy due to the non-self origins. Engineered T cells bearing a TCR (TCR-T) that can specifically recognize the presented HPV antigen become a viable approach to treat this type of cancer. Though engineered T therapies have been well-recognized in hematological cancers, solid cancer treatment has been a major hurdle due to the immune-suppressive tumor microenvironment. One key mechanism of tumor-elicited suppression is the PDL1-PD1 interaction which induces T cell exhaustion. Therefore, TCR-T cells armed with a PD1 antagonist could further enhance the efficacy of TCR-T in solid cancers.


Eligibility Criteria:
Inclusion Criteria:

* Expected to live longer than 12 weeks
* PS 0-2
* Pathology confirmed as HPV16 positive malignant tumor, either metastatic or recurrent disease
* Creatinine \<2.5mg/dl
* ALT/AST is lower than three times ULN.
* No contraindications of leukocyte collection
* Before entering the trial, women must adopt a reliable method of contraception until 30 days after infusion.
* Understand this trial and have signed an informed consent

Exclusion Criteria:

* Patients with symptomatic brain metastasis
* With other uncontrolled malignant tumors.
* Hepatitis B or Hepatitis C activity period, HIV infected patients
* Any other uncontrolled disease that interferes with the trial
* Patients with severe heart and cerebrovascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis and cerebral hemorrhage
* Untreated hypertension or hypertensive patients
* A person with a history of mental illness that is difficult to control
* Researchers do not consider it appropriate to participate in this trial
* Patients who have been using immunosuppressive agents for a long time after organ transplants, except for recent or current inhaled corticosteroids
* Subjects who have been pregnant or nursing, or who plan for pregnancy within 2 months of treatment or after the end of treatment
* An illness affects a person who signs a written consent or complies with a study procedure, or who is unwilling or unable to comply with the research requirements
Innovations in Biofeedback and Its Use in Mental Health

This study investigates the use of new technologies in "biofeedback gaming" and their potential for use as a treatment for stress and anxiety. Biofeedback training is typically accomplished through devices that measure heartrate variability (HRV), galvanic skin response (GSR), or electroencephalogram (EEG). Typically, the use of this equipment requires a practitioner with specialized training in reading and interpreting HRV, GSR, and/or EEG. However, recent advances in technology have made biofeedback devices more readily available to the general public, and some commercial devices are now being sold. This study investigates the utility of these commercial devices with a mild clinical population. In this study, participants use two tools for biofeedback training, one is called "The Pip," described in Group C, below, and another is a computer game called Nevermind, described in Groups A and B, below. These are compared against a control group (group D), which is standard relaxation training without biofeedback.


Eligibility Criteria:
Inclusion criteria:

1. Participant scores at least 1.5 standard deviations above the mean on any anxiety or stress-based scale (BAI or PSS), OR
2. Patient is assigned a CSR of 4 or higher on any anxiety disorder using the ADIS-5, OR
3. Patient exhibits maladaptive coping strategies, as demonstrated by COPE profile, AND
4. Patient shows some level of functional impairment as a result of stress, anxiety, and/or restlessness (i.e. the symptoms are judged by clinician to be clinically meaningful).

Exclusion criteria:

1. Participant is not English-speaking.
2. Participant appears to meet criteria for a comorbid psychiatric diagnosis that warrants alternative psychological treatment (e.g. PTSD, OCD, Major Mood Disorder, Substance Use Disorder, Psychotic Disorder, etc.).
3. Any medical condition that would contraindicate participation in deep breathing practices associated with relaxation training. Some examples may include, but are not limited to, increased intracranial pressure, unstable head or neck injury, active hemorrhage, recent spinal injury, empyema, bronchopleural fistula, flail chest, uncontrolled hypertension, anticoagulation, rib or vertebral fractures or osteoporosis, acute asthma or tuberculosis, recent heart attack, recent skin grafts in chest area, spinal fusions, bony metastases, brittle bones, bronchial hemorrhage, emphysema, untreated pneumothorax, and chest tubes.
4. Any history of epileptic seizure activity which may be worsened by prolonged exposure to a computer screen.
5. Participant is unable to hold small object between thumb and forefinger.
6. Participant is unable to manipulate computer keyboard or computer mouse.
7. Participant has substantial visual deficit in both eyes, which cannot be corrected, that would interfere with ability view a small screen on a mobile device or a laptop screen.
8. Participant is unable to wear a cheststrap heart monitor.
Network Effects of Therapeutic Deep Brain Stimulation

The purpose of this study is to map the acute, short-term cortical evoked responses to thalamic electrical stimulation in persons with intractable epilepsy


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of Epilepsy
* undergoing neuromodulation therapy with clinically implanted neuromodulation devices (DBS, RNS)
* followed in the outpatient epilepsy clinic

Exclusion Criteria:

* pregnant women
* active psychosis, major depression, or suicidal ideation in the preceding year
* Intelligence quotient (IQ) less than 70 as measured by clinical neuropsychological evaluation
* Do not agree to share their medical records for research purposes
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis

This trial studies how well 4 dimensional (D) positron emission tomography/computed tomography (PET/CT) works in diagnosing participants with lung or colorectal cancer that has spread to the liver and lung. Diagnostic procedures, such as PET/CT, may help find and diagnose disease and find out how far the disease has spread. But the motions made by breathing can reduce the image quality of the scan. Adjusting the scanner to 4D may allow for more breathing motion may improve the quality of the PET/CT images.

PRIMARY OBJECTIVES:

I. Study the impact of 4D positron emission tomography/computed tomography (PET/CT) imaging on the evaluation and staging of lung and colorectal cancer.

OUTLINE:

Participants undergo 4D PET/CT scan over up to 12 minutes.

Eligibility Criteria:
Inclusion Criteria:

* Patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study.
* Patients with suspected lung cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study.

Exclusion Criteria:

* Patients that cannot tolerate being scanned for an additional 12 minutes with arms above their head will be excluded.
Nerve Access Tool Study

The purpose of this study is to assess the ability of the nerve access tool to facilitate nerve stimulation lead placement.


Eligibility Criteria:
Inclusion Criteria:

* Subject is equal to or greater than 18 years of age
* Subject has a diagnosis of cystocele with planned surgical repair
* Subject has no known deficit of the nerve
* Subject is willing and able to provide written informed consent and HIPAA authorization to participate by signing the Informed Consent/Health Insurance Portability and Accountability Act Form after a full explanation of the nature and purpose of this study
* Subject is willing and able to comply with the study protocol

Exclusion Criteria:

* Subject has known neurological abnormalities of the nerve
* Subject has a known allergy to the tool or neurostimulation lead components
* Subject is pregnant or lactating
Comparative Study Between Transcoronoid and Infrazygomatic Anterior Maneuvers

new technique in targeting V2 under ultrasound guidance

the classical approach of V2 transcoronoin for practitioner is considered as difficult with significant failure rate with sustained V3 motor stimulation our approach infrazygomatic anterior out of plane is considered much easier in achieving pure V2 stimulation without V3 which make the thermal radio frequency 80 Celsius can be performed safely

Eligibility Criteria:
Inclusion Criteria:above 40 severe pain normal neurological examination -

Exclusion Criteria:metastasis allergy to medication used radio frequency precautions previous failed radio frequency or microvascular decompression gamma knife coagulpathy sepsis or active infection at site of needle entry

-